logo-loader
RNS
viewPhysiomics PLC

Trading Update

/**/ h1{margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;text-align:center;font-size:16.0pt;font-family:"Trebuchet MS","sans-serif";}h3{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Trebuchet MS","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ah{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 72.0pt 89.85pt;}div.ah{}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";text-align: right}p.az{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt}span.av{color:black}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt; text-align: center}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: center; text-autospace: none}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-div: italic; margin-bottom: 0cm; text-align: center; text-autospace: none}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-autospace: none}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify} p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:110%}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: justify}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; line-height: 110%; margin-bottom: 0cm; text-align: justify; text-autospace: none}span.am{font-size:10.0pt; line-height:110%}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:110%;text-autospace:none}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Trebuchet MS","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}span.aj{font-size:10.0pt;color:black} /**/
RNS Number : 0651H
Physiomics PLC
30 July 2019
 

 

30 July 2019

Physiomics plc

("Physiomics") or (the "Company")

 

Trading update

 

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in line with analyst expectations.

 

The Company expects to publish its final audited results for the year ending 30 June 2019 during the week commencing 30 September 2019.

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTPGUUWMUPBGGB

Quick facts: Physiomics PLC

Price: 2.8

Market: AIM
Market Cap: £2.01 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE